Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evolus Inc (EOLS)

Evolus Inc (EOLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,240
  • Shares Outstanding, K 65,060
  • Annual Sales, $ 266,270 K
  • Annual Income, $ -50,420 K
  • EBIT $ -38 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.02
  • Price/Sales 1.22
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 93.49% (+9.40%)
  • Historical Volatility 99.72%
  • IV Percentile 63%
  • IV Rank 11.87%
  • IV High 461.45% on 11/19/25
  • IV Low 43.93% on 06/12/25
  • Expected Move (DTE 14) 0.81 (15.12%)
  • Put/Call Vol Ratio 14.57
  • Today's Volume 109
  • Volume Avg (30-Day) 278
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 14,683
  • Open Int (30-Day) 13,819
  • Expected Range 4.53 to 6.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +16.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.09 +31.62%
on 02/11/26
6.25 -13.84%
on 03/05/26
+0.89 (+19.67%)
since 02/06/26
3-Month
4.09 +31.62%
on 02/11/26
7.34 -26.58%
on 12/17/25
-1.46 (-21.39%)
since 12/05/25
52-Week
4.09 +31.62%
on 02/11/26
13.81 -61.01%
on 03/07/25
-8.11 (-60.11%)
since 03/06/25

Most Recent Stories

More News
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year ...

EOLS : 5.54 (-2.12%)
Evolus to Participate in The Leerink Partners Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...

EOLS : 5.54 (-2.12%)
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year...

EOLS : 5.54 (-2.12%)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026...

EOLS : 5.54 (-2.12%)
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Provides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability 1 Preliminary Unaudited Net Revenue of...

EOLS : 5.54 (-2.12%)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase...

EOLS : 5.54 (-2.12%)
Evolus Reports Third Quarter 2025 Financial Results

Total Net Revenue of $69.0 Million for Q3 2025, Up 13% from Q3 2024; Year-To-Date Growth of 10% Global Jeuveau ® Net...

EOLS : 5.54 (-2.12%)
Evolus to Participate in 2025 Stifel Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...

EOLS : 5.54 (-2.12%)
Evolus to Report Third Quarter Financial Results on November 5, 2025

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial...

EOLS : 5.54 (-2.12%)
Leerink Partners Keeps Their Buy Rating on Evolus (EOLS)

Leerink Partners analyst Marc Goodman maintained a Buy rating on Evolus on October 7. The company’s shares closed yesterday at $6.23.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

EOLS : 5.54 (-2.12%)

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

3rd Resistance Point 6.84
2nd Resistance Point 6.55
1st Resistance Point 6.10
Last Price 5.54
1st Support Level 5.36
2nd Support Level 5.07
3rd Support Level 4.62

See More

52-Week High 13.81
Fibonacci 61.8% 10.10
Fibonacci 50% 8.95
Fibonacci 38.2% 7.80
Last Price 5.54
52-Week Low 4.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar